Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.On November 14, Austin-based Saturn V Capital Management disclosed a significant purchase of Amylyx Pharmaceuticals stock (AMLX 3.73%) that helped increase its position by $41.7 million quarter-over-quarter.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Saturn V Capital Management LP increased its stake in Amylyx Pharmaceuticals (AMLX 3.73%) by 1 ...